Stock Taper
Certara, Inc. provides biosimulation software and services for drug discovery, development, regulatory approval, and market access, serving biopharma, academia, and government worldwide.

An AI-enabled QSP platform that integrates advanced tech and validated models to make quantitative systems pharmacology more accessible and scalable, empowering scientific teams to make better data-driven decisions in drug discovery and development.
| Icon | PRODUCT | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | Reportable Segment | $104.62M | $103.65M ▼ | $106.92M ▲ | $93.27M ▼ |
| Map | REGION | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | Americas | $74M | $72.66M ▼ | $70.25M ▼ | $62.11M ▼ |
![]() | EMEA | $21.91M | $21.56M ▼ | $28.12M ▲ | $20.7M ▼ |
![]() | Asia Pacific | $8.7M | $9.43M ▲ | $8.54M ▼ | $10.46M ▲ |
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
TWST | $145.59 | COMPARE |
TXG | $65.12 | COMPARE |
AVAH | $13.16 | COMPARE |
VCEL | $42.68 | COMPARE |
CLOV | $4.15 | COMPARE |
PGNY | $25.65 | COMPARE |
OMCL | $35.58 | COMPARE |
SDGR | $19.71 | COMPARE |